Osteoarthritis (OA) pain is an extremely prevalent type of chronic pain, affecting more than 30 million individuals in the United States, and is the second-largest segment of the overall chronic pain market. Treatment of OA pain is dominated by cost-effective generic treatments, in addition to costly abuse-deterrent reformulations of opioid analgesics and new combinations of existing analgesics that attempt to mitigate side effects; no truly novel or mechanism-based therapies are currently available. The key drug classes prescribed to treat OA pain, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, are associated with a host of side effects including gastrointestinal, cardiovascular, and/or abuse risks. As such, treatment of this indication can be challenging for physicians because existing therapies are frequently inadequate in achieving long-term analgesia in many patients.
- How is OA pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
- What impact have the recent launches of new analgesics such as Iroko’s Vivlodex and Purdue’s Hysingla ER had on physician prescribing behavior for OA pain?
- What factors drive switching between or discontinuation of select analgesics (e.g., Depomed’s Nucynta ER, Horizon’s Vimovo, Pfizer’s Embeda)?
- How does patient risk for abuse/history of abuse influence physicians’ prescribing of opioid analgesics for OA pain?
Current Treatment: Physician Insights provides physician insights on treatment paths, prescribing behaviors, and the factors and perceptions driving brand usage so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
- Osteoarthritic Pain - Current Treatment - Detailed, Expanded Analysis (US)
Author(s): Bethany A. Kiernan, PhD; Andrea Witt, PhD; Joyce Spadafora, ALM
Bethany A. Kiernan, Ph.D., is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders.
Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her Ph.D. degree from Case Western Reserve University.
Andrea S. Witt, Ph.D., is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.
Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.
Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.